Business Context and Reporting Period
This Form 6-K filing by Dr. Reddy's Laboratories Limited, dated November 15, 2006, reports on an "Other Event" regarding the filing of a Shelf Registration Statement (Form F-3) and a Prospectus Supplement on November 13, 2006. The filing details an offering of 13,500,000 American Depositary Shares (ADSs). The financial data presented reflects the company's position as of September 30, 2006, with pro forma adjustments based on an assumed offering price of U.S.$17.22 per ADS.
Key Financial Metrics
The filing provides capitalization and liquidity data as of September 30, 2006, prepared in accordance with U.S. GAAP. It does not contain revenue, profit, or cash flow statements for a specific operating period.
| Metric | Actual (Rs. in thousands) | Actual (U.S.$ in thousands) | Pro Forma (Rs. in thousands) | Pro Forma (U.S.$ in thousands) |
|---|---|---|---|---|
| Cash and Cash Equivalents | 4,875,531 | 106,105 | 15,557,528 | 338,575 |
| Total Short-Term Debt | 11,753,146 | 255,781 | 11,753,146 | 255,781 |
| Total Long-Term Debt | 20,607,472 | 448,476 | 20,607,472 | 448,476 |
| Total Stockholders' Equity | 26,506,384 | 576,853 | 37,188,381 | 809,323 |
| Total Capitalization | 58,867,002 | 1,281,110 | 69,548,999 | 1,513,580 |
Net Tangible Book Value: As of June 30, 2006, the net tangible book value was Rs.156.75 per equity share (U.S.$3.42 per ADS). Pro forma, following the offering, this is estimated to increase to Rs.207.96 per equity share (U.S.$4.53 per ADS).
Material Changes
The primary material change described is the pro forma impact of the proposed ADS offering on the company's capital structure:
- Cash Position: Cash and cash equivalents are projected to increase by approximately Rs.10.68 billion (U.S.$232.5 million) upon completion of the offering.
- Equity: Total stockholders' equity is projected to increase by approximately Rs.10.68 billion (U.S.$232.5 million).
- Dilution: New investors face an immediate dilution of Rs.581.92 per equity share (U.S.$12.69 per ADS), representing 75.25% of the offering price. Existing shareholders would see an immediate increase in net tangible book value of Rs.51.21 per share (U.S.$1.11 per ADS).
Outlook, Risks, and Unusual Items
The filing does not provide management commentary on future operational outlook, risks, or contingencies beyond the mechanics of the offering. The document notes that the pro forma figures assume the underwriters' over-allotment option is not exercised. It further states that for every U.S.$1.00 increase in the assumed offering price, cash and equity would increase by Rs.620.3 million (U.S.$13.5 million).
Investor Verification Checklist
- Verify the final offering price and the number of ADSs sold, as the pro forma figures are based on an assumed price of U.S.$17.22 and 13,500,000 shares.
- Confirm whether the underwriters' over-allotment option was exercised, which would alter the capitalization figures.
- Review the full Prospectus Supplement and Shelf Registration Statement (File No. 333-138608) for detailed risk factors and use of proceeds not included in this summary.
- Check the exchange rate used for conversions (Rs.45.95 per U.S.$1.00 as of September 30, 2006) against current rates for accurate valuation.